Roche, AmorChem partner for myotonic muscular dystrophy

Roche (SIX:ROG; OTCQX:RHHBY) partnered with VC fund AmorChem L.P. (Montreal, Quebec) to discover small molecules to treat myotonic muscular dystrophy type 1. Discovery will take place at AmorChem's medicinal chemistry incubator NuChem Therapeutics Inc. using technology discovered by University of Montreal. In 2013, the university granted AmorChem exclusive rights to develop and commercialize the technology, which generated compounds that disrupt RNA foci formation and repair RNA splicing defects caused by a mutation in the dystrophia myotonica-protein kinase (DMPK) gene. ...